ICICI Direct is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 470 in its research report dated August 06, 2020.
ICICI Direct's research report on Cadila Healthcare
Q1 revenues grew 4.1% YoY to Rs 3640 crore (I-direct estimate: Rs 3584 crore). US sales grew a robust 18.7% YoY to Rs 1623 crore. Domestic formulations de-grew 11.2% YoY to Rs 829 crore. Wellness segment de-grew 12.3% YoY to Rs 532 crore. API segment grew 89.2% YoY to 131 crore. EBITDA margins expanded 433 bps YoY to 22.4% (I-direct estimate: 19.4%) due to better gross margin performance and lower other expenses. Subsequently, EBITDA grew 29.0% YoY to Rs 815 crore (I-direct estimate: Rs 697 crore). PAT grew 49.4% YoY to Rs 454 crore (I-direct estimates: Rs 365 crore). Delta vis-à-vis EBITDA was mainly due to lower interest cost.
We arrive at our target price of Rs 470 based on 22x FY22E EPS of Rs 21.3.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.